Might Combined GABAA Agonists and NMDA Antagonists have a Therapeutic and maybe a Prophylactic Effect in Alzheimer's and Parkinson's Disease?Felix-Martin Werner1,2* and Rafael Coveñas2
- *Corresponding Author:
- Felix-Martin Werner
University of Salamanca
Instituto de Neurociencias de Castilla y León (INCYL)
Laboratorio de Neuroanatomía de los Sistemas Peptidérgicos (Lab. 14)
c/ Pintor Fernando Gallego, 137007-Salamanca, Spain
Tel: +34/923/29 44 00, extn 1856
Fax: +34/923/29 45 49
E-mail: [email protected] versanet.de
Received date: November 01, 2014; Accepted date: December 24, 2014; Published date:December 19, 2012
Citation:Werner FM, Covenas R (2014) Might Combined GABAA Agonists and NMDA Antagonists have a Therapeutic and maybe a Prophylactic Effect in Alzheimer’s and Parkinson’s Disease?. J Cytol Histol 6:298. doi:10.4172/2157-7099.1000298
Copyright: © 2014 Werner FM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Alzheimer’s and Parkinson’s diseases are neurodegenerative diseases which cannot be cured so far. In both diseases, a GABAergic-glutaminergic neurotransmitter imbalance might occur. Neural networks are suggested for Parkinson’s disease in the extrapyramidal system and for Alzheimer’s disease in the hippocampus and the temporal cortex. Combined GABAA agonists and NMDA antagonists might have therapeutic and maybe prophylactic properties in Alzheimer’s and Parkinson’s disease. It is important to examine the neural networks in the brain areas involved in both diseases. This would offer the possibility to try an early beginning pharmacotherapy of these, up to now, incurable diseases.